Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination

Carcinogenesis

Volumn 34, Issue 11, 2013, Pages 2593-2599

  Bhattacharya, Arup ^a   Li, Yun ^a   Shi, Yi ^a   Zhang, Yuesheng ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYL ISOTHIOCYANATE; CASPASE; CELECOXIB; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; LOW DRUG DOSE; MUSCLE CANCER; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CASPASES; CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; ENDOTHELIUM, VASCULAR; FEMALE; FOOD PRESERVATIVES; HUMANS; ISOTHIOCYANATES; MUSCLE, SKELETAL; NEOPLASM INVASIVENESS; PYRAZOLES; RATS; RATS, INBRED F344; SULFONAMIDES; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84887003536     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt280     Document Type: Article

References (33)

1. Zhang,Y. (2010) Allyl isothiocyanate as a cancer chemopreventive phytochemical. Mol. Nutr. Food Res., 54, 127-135.
2. Krul,C. et al. (2002) Metabolism of sinigrin (2-propenyl glucosinolate) by the human colonic microflora in a dynamic in vitro large-intestinal model. Carcinogenesis, 23, 1009-1016.
3. Bhattacharya,A. et al. (2010) Allyl isothiocyanate-rich mustard seed powder inhibits bladder cancer growth and muscle invasion. Carcinogenesis, 31, 2105-2110.
4. Tang,L. et al. (2004) Dietary isothiocyanates inhibit the growth of human bladder carcinoma cells. J. Nutr., 134, 2004-2010.
5. Tang,L. et al. (2006) The principal urinary metabolites of dietary isothiocyanates, N-acetylcysteine conjugates, elicit the same anti-proliferative response as their parent compounds in human bladder cancer cells. Anticancer. Drugs, 17, 297-305.
6. Ioannou,Y.M. et al. (1984) Allyl isothiocyanate: comparative disposition in rats and mice. Toxicol. Appl. Pharmacol., 75, 173-181.
7. Bollard,M. et al. (1997) The disposition of allyl isothiocyanate in the rat and mouse. Food Chem. Toxicol., 35, 933-943.
8. Munday,R. et al. (2006) Evaluation of isothiocyanates as potent inducers of carcinogen-detoxifying enzymes in the urinary bladder: critical nature of in vivo bioassay. Nutr. Cancer, 54, 223-231.
9. Bhattacharya,A. et al. (2010) Inhibition of bladder cancer development by allyl isothiocyanate. Carcinogenesis, 31, 281-286.
10. Bhattacharya,A. et al. (2012) The principal urinary metabolite of allyl isothiocyanate, N-acetyl-S-(N-allylthiocarbamoyl)cysteine, inhibits the growth and muscle invasion of bladder cancer. Carcinogenesis, 33, 394-398.
11. Geng,F. et al. (2011) Allyl isothiocyanate arrests cancer cells in mitosis, and mitotic arrest in turn leads to apoptosis via Bcl-2 protein phosphorylation. J. Biol. Chem., 286, 32259-32267.
12. Mohammed,S.I. et al. (1999) Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res., 59, 5647-5650.
13. Klein,R.D. et al. (2005) Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res., 65, 1808-1813.
14. Mokos,I. et al. (2006) Association of cyclooxygenase-2 immunoreactivity with tumor recurrence and disease progression in superficial urothelial bladder cancer. Tumori, 92, 124-129.
15. Kim,S.I. et al. (2002) Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology, 60, 816-821.
16. Moon,R.C. et al. (1993) Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis, 14, 1487-1489.
17. Kitayama,W. et al. (1999) Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis, 20, 2305-2310.
18. Grubbs,C.J. et al. (2000) Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res., 60, 5599-5602.
19. Rao,K.V. et al. (1996) Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis, 17, 1435-1438.
20. Mohammed,S.I. et al. (2006) Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol. Cancer Ther., 5, 329-336.
21. Pagliarulo,V. et al. (2008) Celecoxib for the treatment of non muscle invasive bladder cancer. Results from the first phase 11 clinical trial. Eur. Urol. Suppl., 7, 299.
22. Sabichi,A.L. et al. (2011) A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev. Res. (Phila)., 4, 1580-1589.
23. Kelly,J.D. et al. (2011) Boxing bladder cancer with COX-2-specific inhibition. Cancer Prev. Res. (Phila)., 4, 1534-1535.
24. Cohen,S.M. et al. (1981) Transplantation and cell culture of rat urinary bladder carcinoma. Invest. Urol., 19, 136-141.
25. Trifan,O.C. et al. (2002) Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res., 62, 5778-5784.
26. Nie,D. et al. (2002) Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell. Mol. Life Sci., 59, 799-807.
27. Dhawan,D. et al. (2010) Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol. Cancer Ther., 9, 1371-1377.
28. Wei,D. et al. (2004) Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res., 64, 2030-2038.
29. Bhattacharya,A. et al. (2008) Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin. Cancer Res., 14, 3926-3932.
30. Bhattacharya,A. et al. (2009) Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. Clin. Colorectal Cancer, 8, 155-162.
31. Hennekens,C.H. et al. (2008) Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J. Cardiovasc. Pharmacol. Ther., 13, 41-50.
32. Solomon,S.D. et al.; APC and PreSAP Trial Investigators. (2006) Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 114, 1028-1035.
33. Bertagnolli,M.M. et al.; Adenoma Prevention with Celecoxib Study Investigators. (2009) Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev. Res. (Phila)., 2, 310-321.